BDBM305163 US10144734, Example 179::US10172845, Example 179::US10441581, Example 179::US10881652, Example 179::US11648243, Example 179

SMILES COc1ccc(OC2CN(C2)c2ccc(cn2)-c2cc(OCC(C)(C)O)cn3ncc(C#N)c23)nn1

InChI Key InChIKey=CXCWBZZDSRWUGA-UHFFFAOYSA-N

Data  10 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 10 hits for monomerid = 305163   

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Homo sapiens (Human))
Array Biopharma

US Patent
LigandPNGBDBM305163(US10144734, Example 179 | US10172845, Example 179 ...)
Affinity DataIC50:  27.1nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE-TK assay techn...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804M](Homo sapiens (Human))
Array Biopharma

US Patent
LigandPNGBDBM305163(US10144734, Example 179 | US10172845, Example 179 ...)
Affinity DataIC50:  139nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE-TK assay techn...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProto-oncogene tyrosine-protein kinase receptor Ret [658-1114](Homo sapiens (Human))
Array Biopharma

US Patent
LigandPNGBDBM305163(US10144734, Example 179 | US10172845, Example 179 ...)
Affinity DataIC50:  27.1nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF® KinEASE-TK assay tech...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProto-oncogene tyrosine-protein kinase receptor Ret [658-1114,V804M](Homo sapiens (Human))
Array Biopharma

US Patent
LigandPNGBDBM305163(US10144734, Example 179 | US10172845, Example 179 ...)
Affinity DataIC50:  139nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF® KinEASE-TK assay tech...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804M](Homo sapiens (Human))
Array Biopharma

US Patent
LigandPNGBDBM305163(US10144734, Example 179 | US10172845, Example 179 ...)
Affinity DataIC50:  139nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF® KinEASE™-TK assay tec...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProto-oncogene tyrosine-protein kinase receptor Ret [G810R](Homo sapiens (Human))
Array Biopharma

US Patent
LigandPNGBDBM305163(US10144734, Example 179 | US10172845, Example 179 ...)
Affinity DataIC50:  139nMAssay Description:The potency of a compound inhibiting G810R mutant RET kinase was determined using CisBio's HTRF Kinease-TK assay technology. The assays contained...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProto-oncogene tyrosine-protein kinase receptor Ret(Homo sapiens (Human))
Array Biopharma

US Patent
LigandPNGBDBM305163(US10144734, Example 179 | US10172845, Example 179 ...)
Affinity DataIC50:  27.1nMAssay Description:Wildtype and V804M mutant: Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804M](Homo sapiens (Human))
Array Biopharma

US Patent
LigandPNGBDBM305163(US10144734, Example 179 | US10172845, Example 179 ...)
Affinity DataIC50:  139nMAssay Description:Wildtype and V804M mutant: Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProto-oncogene tyrosine-protein kinase receptor Ret [658-1114,V804M](Homo sapiens (Human))
Array Biopharma

US Patent
LigandPNGBDBM305163(US10144734, Example 179 | US10172845, Example 179 ...)
Affinity DataIC50:  27.1nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF® KinEASE™-TK assay tec...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProto-oncogene tyrosine-protein kinase receptor Ret [658-1114,V804M](Homo sapiens (Human))
Array Biopharma

US Patent
LigandPNGBDBM305163(US10144734, Example 179 | US10172845, Example 179 ...)
Affinity DataIC50:  27.1nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE-TK assay techn...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent